The FDA granted Breakthrough Therapy Designations for AbbVie's investigational ADC Temab-A in colorectal cancer (combo with bevacizumab) and non-small cell lung cancer (monotherapy). The designations are based on Phase 1 data and mark the first BTDs for this asset.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
